AAAAI News: Neffy Performs Well in Phase 2 CSU Study
Neffy, a needle-free epinephrine nasal spray, showed statistically significant and clinically meaningful improvement in pruritus, hives, body surface area and erythema in treatment-resistant chronic spontaneous urticaria (CSU) patients, according to phase 2 data presented at the 2024 American Academy of Allergy, Asthma and Immunology (AAAAI) in Washington, D.C. The trial met its primary endpoints with […]